Suggested remit: To appraise the clinical and cost effectiveness of talquetamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 5082
Provisional Schedule
- Committee meeting:
- 12 August 2025
- Expected publication:
- 15 October 2025
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Johnson & Johnson (talquetamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Myeloma UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- UK Myeloma Society
- Associated public health groups
- None
- Comparator companies
- GlaxoSmithKline (belantamab) (confidentiality agreement signed, participating)
- Menarini Stemline (selinexor) (confidentiality agreement signed, participating)
- Pfizer (bortezomib) (confidentiality agreement signed, participating)
- Sanofi (isatuximab) (confidentiality agreement signed, participating)
- Aspire Pharma (bortezomib) (confidentiality agreement not signed, not participating)
- Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating)
- Biotech Pharma (bortezomib) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (pomalidomide) (confidentiality agreement not signed, not participating)
- Dr Reddy’s Laboratories (bortezomib) (confidentiality agreement not signed, not participating)
- Johnson & Johnson (bortezomib, teclistamab) (confidentiality agreement not signed, not participating)
- MSN Laboratories Europe (bortezomib) (confidentiality agreement not signed, not participating)
- Pharmaand GmbH (panobinostat) (confidentiality agreement not signed, not participating) (confidentiality agreement not signed, not participating)
- Sandoz (bortezomib) (confidentiality agreement not signed, not participating)
- Sun Pharma (bortezomib) (confidentiality agreement not signed, not participating)
- Thornton and Ross (bortezomib) (confidentiality agreement not signed, not participating)
- Tillomed Laboratories (bortezomib) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 January 2025 | Invitation to participate |
| 06 November 2024 - 04 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5082 |
| 06 November 2024 | In progress. Scoping commencing |
| 23 February 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual